How to commercialize Biosimilars? Case studies from Boehringer Ingelheim, EMD Serono and Teva

Top Quote SMi Group reports: Boehringer Ingelheim, EMD Serono and Teva will be presenting at this year's Biosimilars North America meeting in New Jersey, USA on November 16 - 17. End Quote
  • (1888PressRelease) July 14, 2016 - It's without doubts that the biosimilars market present lucrative opportunities for pharmaceuticals and biotech companies. Over the last 12 months, market participants have witnessed revolutionary steps in the US to facilitate commercialization. There are now 2 biosimilars approved, with a growing number expected to enter the market across a broad range of therapeutic areas within the next few years.

    The 3rd annual Biosimilars North America conference (Nov 16- 17, 2016, Renaissance Woodbridge Hotel, Iselin, New Jersey, USA) will gather leading industry experts and learn how to de-risk and develop a holistic value chain for biosimilars commercialization.

    SMi group is delighted to have Molly Burich, Associate Director, Public Policy - Biosimilars, Pipeline, Reimbursement, Boehringer Ingelheim Pharmaceuticals, presenting on considerations for commercial success. Molly will focus on the big question of reimbursement of biosimilars in the US - what's the future and challenges?

    Catherine Godrecka-Bareau, Director Strategy & Portfolio Management, Biosimilars, EMD Serono will be speaking about industry partnerships: key success factors in biosimilar space.

    Biosimilars - from aspiration to operations will be discussed by Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals. Edric will be focusing on corporate strategy, portfolio strategy and organizational implications.

    Furthermore, auditory will hear exclusive case studies from Canada and China.

    For more information about the event please visit:

    Unrivalled speaker line up in 2016 includes:
    - Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
    - Gustavo Grampp, Ph.D., Director R&D Policy - Biosimilars, Amgen Inc.
    - Andrew Simpson, Scientifi c Director, Orygen Biotechnologia S/A
    - Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
    - Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfizer Inc., and many more.

    Conference will also feature two interactive pre-conference workshops:
    A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research
    Led by Shazia Ahmad, Director, Patient & Physician Services, UBC - An Express Scripts Company

    B: Biosimilars: Considerations for Optimizing Access and Price
    Led by: Mkaya Mwamburi, Vice President, HEOR/Evidence Generation, MKTX Market Access Solutions, LLC

    2016 event is sponsored by: Abzena, Schwegman, Lundberg & Woessner, P.A. and Wyatt Health Management

    For media enquiries please contact Anna Serazetdinova on +44 20 7827 6180 or aserazetdinova ( @ ) smi-online dot co dot uk
    For delegate enquiries contact Fateja Begum +44 (0) 20 7827 6184 or email fbegum ( @ ) smi-online dot co dot uk
    For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick ( @ ) smi-online dot co dot uk

    About SMi Group:
    Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

  • FB Icon Twitter Icon In-Icon
Contact Information